BridgeBio, Kyowa Kirin Ink Partnership With An Upfront Payment Of $100M For Exclusive License On Infigratinib In Skeletal Dysplasias In Japan
Portfolio Pulse from Benzinga Newsdesk
BridgeBio and Kyowa Kirin have formed a partnership, granting Kyowa Kirin an exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan. BridgeBio will receive an upfront payment of $100M, royalties up to the high-twenties percent on sales in Japan, and potential additional milestone-based payments.
February 07, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BridgeBio receives a $100M upfront payment from Kyowa Kirin for the exclusive license of infigratinib in Japan, plus royalties and potential milestone payments.
The upfront payment of $100M, along with royalties and potential milestone payments, directly benefits BridgeBio financially. This partnership could significantly boost BridgeBio's revenue stream from the Japanese market, making it a positive development for the company's financial outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90